LY 3475070 / Eli Lilly - LARVOL DELTA

KEYNOTE A57: A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer (clinicaltrials.gov) - P1 | N=52 | Completed | Sponsor: Eli Lilly and Company | Active, not recruiting ➔ Completed | N=150 ➔ 52

Combination therapy • Enrollment change • Monotherapy • Trial completion • Breast Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor

KEYNOTE A57: A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer (clinicaltrials.gov) - P1 | N=150 | Active, not recruiting | Sponsor: Eli Lilly and Company | Trial completion date: Dec 2021 ➔ Jun 2022

Combination therapy • Monotherapy • Trial completion date • Breast Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor

KEYNOTE A57: A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer (clinicaltrials.gov) - P1; N=150; Active, not recruiting; Sponsor: Eli Lilly and Company; Recruiting ➔ Active, not recruiting; Trial completion date: Dec 2022 ➔ Dec 2021

Clinical • Combination therapy • Enrollment closed • Monotherapy • Trial completion date • Breast Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer (clinicaltrials.gov) - P1; N=120; Recruiting; Sponsor: Eli Lilly and Company; Suspended ➔ Recruiting

Clinical • Combination therapy • Enrollment open • Monotherapy • Breast Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Thoracic Cancer

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer (clinicaltrials.gov) - P1; N=120; Suspended; Sponsor: Eli Lilly and Company; Recruiting ➔ Suspended

Clinical • Combination therapy • Monotherapy • Trial suspension • Breast Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Gynecologic Cancers • Lung Cancer • Melanoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Thoracic Cancer • Urothelial Cancer

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer (clinicaltrials.gov) - P1; N=120; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting

Clinical • Combination therapy • Enrollment open • Monotherapy